Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Neurology

What Medications Treat Myotonia in Myotonic Dystrophy?

At a Glance

Mexiletine is the standard and most effective medication for treating myotonia (muscle locking) in myotonic dystrophy. Because both the condition and the medication can affect the heart's electrical system, patients must undergo strict, ongoing cardiac monitoring while taking this treatment.

Yes, there are medications that can effectively reduce the muscle locking (myotonia) you experience in your hands and other muscles. The most commonly prescribed treatment is a drug called mexiletine, which works by calming the electrical signals within your muscle cells [1]. However, because myotonic dystrophy inherently affects the heart, and anti-myotonia medications can also impact heart rhythm, taking these drugs requires a careful balance and frequent cardiac monitoring to ensure your safety [2].

Understanding How These Medications Work

Myotonia—the delayed relaxation of muscles after you use them—happens because the electrical signals in your muscle cells become hyperexcitable, causing them to fire repeatedly [3]. Medications used to treat this are typically sodium channel blockers. They work by limiting the flow of sodium into the muscle cells, which acts like a brake on the electrical signals, helping your muscles relax normally after you grip something [1].

Before starting medication, many patients find some relief through non-medical strategies, such as taking advantage of the “warm-up effect” (where muscles relax more easily after repeated movements) or keeping their hands warm to avoid cold triggers, which can worsen muscle locking.

The Standard Treatment: Mexiletine

Mexiletine is currently the gold standard and most effective medication for managing myotonia in both Type 1 and Type 2 myotonic dystrophy [4][5]. Studies show it significantly improves muscle stiffness and overall quality of life for many patients [6][7].

Treatment usually starts at a low dose and is gradually increased by your doctor based on your symptom relief and any side effects [8]. As you reach an effective dose, you may notice improvements in your muscle relaxation relatively quickly, though it can take a period of dose adjustments to find the right balance for your body.

The Crucial Heart Connection

The most important thing to understand before starting mexiletine is the relationship between the drug and your heart. Myotonic dystrophy itself carries a significant risk of cardiac issues, particularly arrhythmias (irregular heartbeats) and conduction delays (slowed electrical signals in the heart) [9][10].

Mexiletine is an anti-arrhythmic drug, meaning it directly affects the heart’s electrical system [11]. Because of this, clinical experts require much stricter cardiac monitoring for patients with myotonic dystrophy than for people taking the drug for other conditions [2].

  • Baseline Testing: Before starting mexiletine, you must have an ECG (electrocardiogram) to ensure you do not have pre-existing severe heart block or conduction delays [8]. Even mild delays found before starting the medication can predict future heart complications while on the drug [8].
  • Ongoing Monitoring: Once on the medication, you will need routine, serial cardiac surveillance (such as regular ECGs or Holter monitors) to ensure the drug isn’t negatively affecting your heart rhythm [9][11].
  • Warning Signs to Watch For: In addition to clinical testing, it is crucial to know what a heart complication feels like. If you experience palpitations (a racing or fluttering heart), sudden dizziness, lightheadedness, or fainting while on this medication, you should seek immediate medical attention and contact your doctor.

Potential Side Effects

While long-term use of mexiletine is generally considered safe when carefully monitored [4], it does have side effects. The most common and dose-limiting side effect is dyspepsia (severe indigestion or upset stomach) and other gastrointestinal issues [12][13]. Taking the medication with food or adjusting the dose with your doctor’s guidance can often help manage this.

Are There Other Options?

If you cannot take mexiletine due to heart issues or severe stomach side effects, doctors sometimes consider other medications like lamotrigine, an anti-seizure drug [14]. However, comparative evidence between mexiletine and alternative medications is limited, and they are not always considered as consistently effective as mexiletine for this specific symptom [14].

Common questions in this guide

What is the best medication for muscle locking in myotonic dystrophy?
The most commonly prescribed and effective medication for muscle locking is mexiletine. It is a sodium channel blocker that works by calming the hyperexcitable electrical signals in your muscle cells, allowing them to relax normally after use.
Why do I need heart tests if I take medication for myotonia?
Myotonic dystrophy naturally increases your risk for heart rhythm issues, and medications like mexiletine also affect the heart's electrical system. Your doctor will require routine ECGs or Holter monitors to ensure the drug is not causing dangerous arrhythmias or conduction delays.
What are the side effects of mexiletine?
The most common side effect of mexiletine is dyspepsia, which includes severe indigestion and upset stomach. Doctors often recommend taking the medication with food or adjusting your dose to help manage these gastrointestinal issues.
Are there alternatives to mexiletine if I have heart problems?
If mexiletine is unsafe for your heart or causes unmanageable stomach issues, doctors might try an anti-seizure medication called lamotrigine. However, alternative medications are generally not considered as consistently effective for myotonia as mexiletine.
Can I reduce muscle locking without taking medication?
Yes, before starting medication, many patients manage symptoms by keeping their hands warm to avoid cold triggers. You can also use the warm-up effect, which means repeatedly moving the muscle until it begins to relax more easily.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Do my current heart tests show any conduction delays that would make starting mexiletine risky?
  2. 2.If I start mexiletine, exactly how often will I need a follow-up ECG or Holter monitor?
  3. 3.What specific cardiac symptoms should prompt me to stop taking the medication and call you immediately?
  4. 4.Should I consult with a specialized cardiologist before starting an anti-myotonic medication?
  5. 5.How should I manage the common gastrointestinal side effects if I decide to start this treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Muscle velocity recovery cycles as pharmacodynamic biomarker: Effects of mexiletine in a randomized double-blind placebo-controlled cross-over study.

    Ruijs TQ, Koopmans IW, de Kam ML, et al.

    Clinical and translational science 2022; (15(12)):2971-2981 doi:10.1111/cts.13418.

    PMID: 36281627
  2. 2

    Expert opinion on mexiletine treatment in adult patients with myotonic dystrophy.

    Wahbi K, Bassez G, Duchateau J, et al.

    Archives of cardiovascular diseases 2024; (117(6-7)):450-456 doi:10.1016/j.acvd.2024.03.001.

    PMID: 38677940
  3. 3

    Neuromuscular excitability changes produced by sustained voluntary contraction and response to mexiletine in myotonia congenita.

    Ginanneschi F, Mignarri A, Lucchiari S, et al.

    Neurophysiologie clinique = Clinical neurophysiology 2017; (47(3)):247-252 doi:10.1016/j.neucli.2017.01.003.

    PMID: 28153715
  4. 4

    Long-term Safety and Efficacy of Mexiletine in Myotonic Dystrophy Types 1 and 2.

    Mousele C, Matthews E, Pitceathly RDS, et al.

    Neurology. Clinical practice 2021; (11(5)):e682-e685 doi:10.1212/CPJ.0000000000001073.

    PMID: 34840883
  5. 5

    A review of the use of mexiletine in patients with myotonic dystrophy and non-dystrophic myotonia.

    D'Mello S, Shum L

    European journal of hospital pharmacy : science and practice 2016; (23(6)):359-363 doi:10.1136/ejhpharm-2015-000839.

    PMID: 31156883
  6. 6

    Efficacy and safety of mexiletine in non-dystrophic myotonias: A randomised, double-blind, placebo-controlled, cross-over study.

    Vicart S, Franques J, Bouhour F, et al.

    Neuromuscular disorders : NMD 2021; (31(11)):1124-1135 doi:10.1016/j.nmd.2021.06.010.

    PMID: 34702654
  7. 7

    Expert Insights from a Delphi-driven Neurologists' Panel: Real-world Mexiletine use in Patients with Myotonic Disorders in Italy.

    Lidonnici D, Brambilla P, Ravasio R, et al.

    Journal of neuromuscular diseases 2024; (11(2)):411-423 doi:10.3233/JND-230115.

    PMID: 38306059
  8. 8

    Evaluation of mexiletine effect on conduction delay and bradyarrhythmic complications in patients with myotonic dystrophy type 1 over long-term follow-up.

    Vio R, Zorzi A, Bello L, et al.

    Heart rhythm 2020; (17(11)):1944-1950 doi:10.1016/j.hrthm.2020.05.043.

    PMID: 32525073
  9. 9

    Cardiac Involvement and Arrhythmias Associated with Myotonic Dystrophy.

    McBride D, Deshmukh A, Shore S, et al.

    Reviews in cardiovascular medicine 2022; (23(4)) doi:10.31083/j.rcm2304126.

    PMID: 36177340
  10. 10

    Risk of Cardiac Disease in a Population-Based Cohort of Myotonic Dystrophy Type 1 and Type 2 in the United States.

    Johnson NE, Bhandaru V, Andrews JG, et al.

    Neurology. Genetics 2025; (11(6)):e200322 doi:10.1212/NXG.0000000000200322.

    PMID: 41170323
  11. 11

    Recommendations of an expert group for the cardiac assessment of non-dystrophic myotonia adult patients treated with mexiletine.

    Vicart S, Wahbi K, Duchateau J, et al.

    Neuromuscular disorders : NMD 2024; (44()):104464 doi:10.1016/j.nmd.2024.104464.

    PMID: 39368428
  12. 12

    Effectiveness and safety of mexiletine versus placebo in patients with myotonia: a systematic review and meta-analysis.

    Elettreby AM, Elnaga AAA, Alsaied MA, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2024; (45(8)):3989-4001 doi:10.1007/s10072-024-07412-z.

    PMID: 38403671
  13. 13

    Long-Term Safety and Usefulness of Mexiletine in a Large Cohort of Patients Affected by Non-dystrophic Myotonias.

    Modoni A, D'Amico A, Primiano G, et al.

    Frontiers in neurology 2020; (11()):300 doi:10.3389/fneur.2020.00300.

    PMID: 32655465
  14. 14

    Mexiletine versus lamotrigine in non-dystrophic myotonias: a randomised, double-blind, head-to-head, crossover, non-inferiority, phase 3 trial.

    Vivekanandam V, Skorupinska I, Jayaseelan DL, et al.

    The Lancet. Neurology 2024; (23(10)):1004-1012 doi:10.1016/S1474-4422(24)00320-X.

    PMID: 39304240

This page provides educational information about myotonia treatments in myotonic dystrophy. Because these medications can affect heart rhythm, always consult your neurologist and cardiologist to determine the safest treatment plan for you.

Get notified when new evidence is published on Myotonic dystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.